Characterization of angiotensin II molecular determinants involved in AT1 receptor functional selectivity

Molecular Pharmacology

Volumn 87, Issue 6, 2015, Pages 982-995

  Domazet, Ivana ^a   Holleran, Brian J ^a   Richard, Alexandra ^a   Vandenberghe, Camille ^a   Lavigne, Pierre ^a   Escher, Emanuel ^a   Leduc, Richard ^a   Guillemette, Gaétan ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; BETA ARRESTIN; BETA ARRESTIN 1; BETA ARRESTIN 2; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; PROTEIN KINASE C ZETA; SMALL INTERFERING RNA; EGFR PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; ISOENZYME; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OLIGOPEPTIDE; RETINA S ANTIGEN;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; CONTROLLED STUDY; EMBRYO; ENZYME PHOSPHORYLATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; ISOMER; LUMINESCENCE; PRIORITY JOURNAL; TRANSACTIVATION; WESTERN BLOTTING; CHEMISTRY; ENZYME ACTIVATION; METABOLISM; SIGNAL TRANSDUCTION; SYNTHESIS;

ANGIOTENSIN II; ARRESTINS; ENZYME ACTIVATION; GTP-BINDING PROTEIN ALPHA SUBUNITS, G12-G13; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HEK293 CELLS; HUMANS; ISOENZYMES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OLIGOPEPTIDES; PROTEIN KINASE C; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84936098174     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.097337     Document Type: Article

References (33)

1. Ahn S, Shenoy SK, Wei H, and Lefkowitz RJ (2004a) Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem 279:35518-35525.
2. Ahn S, Wei H, Garrison TR, and Lefkowitz RJ (2004b) Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by beta-arrestins 1 and 2. J Biol Chem 279:7807-7811.
3. Corpet F (1988) Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 16:10881-10890.
4. de Gasparo M, Catt KJ, Inagami T, Wright JW, and Unger T (2000) International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52:415-472.
5. Evans BA, Sato M, Sarwar M, Hutchinson DS, and Summers RJ (2010) Ligand-directed signalling at beta-adrenoceptors. Br J Pharmacol 159:1022-1038.
6. Galandrin S, Oligny-Longpré G, and Bouvier M (2007) The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 28:423-430.
7. Gohla A, Schultz G, and Offermanns S (2000) Role for G(12)/G(13) in agonist-induced vascular smooth muscle cell contraction. Circ Res 87:221-227.
8. Hall MM, Khosla MC, Khairallah PA, and Bumpus FM (1974) Angiotensin analogs: the influence of sarcosine substituted in position 1. J Pharmacol Exp Ther 188:222-228.
9. Holloway AC, Qian H, Pipolo L, Ziogas J, Miura S, Karnik S, Southwell BR, Lew MJ, and Thomas WG (2002) Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol 61:768-777.
10. Hunyady L and Catt KJ (2006) Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 20:953-970.
11. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
12. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, and Novick S (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3:193-203.
13. Kim J, Ahn S, Rajagopal K, and Lefkowitz RJ (2009) Independent beta-arrestin2 and Gq/protein kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. J Biol Chem 284:11953-11962.
14. Liao DF, Monia B, Dean N, and Berk BC (1997) Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. J Biol Chem 272:6146-6150.
15. Luttrell LM (2002) Activation and targeting of mitogen-activated protein kinases by G-protein-coupled receptors. Can J Physiol Pharmacol 80:375-382.
16. Miura S, Feng YH, Husain A, and Karnik SS (1999) Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. J Biol Chem 274: 7103-7110.
17. Miura S, Zhang J, Matsuo Y, Saku K, and Karnik SS (2004) Activation of extracellular signal-activated kinase by angiotensin II-induced Gq-independent epidermal growth factor receptor transactivation. Hypertens Res 27:765-770.
18. Regoli D, Park WK, and Rioux F (1974) Pharmacology of angiotensin. Pharmacol Rev 26:69-123.
19. Rominger DH, Cowan CL, Gowen-MacDonald W, and Violin JD (2014) Biased ligands: pathway validation for novel GPCR therapeutics. Curr Opin Pharmacol 16:108-115.
20. Sagara Y, Hirooka Y, Nozoe M, Ito K, Kimura Y, and Sunagawa K (2007) Pressor response induced by central angiotensin II is mediated by activation of Rho/Rho-kinase pathway via AT1 receptors. J Hypertens 25:399-406.
21. Samanen J, Cash T, Narindray D, Brandeis E, Yellin T, and Regoli D (1989) The role of position 4 in angiotensin II antagonism: a structure-activity study. J Med Chem 32:1366-1370.
22. Shonberg J, Lopez L, Scammells PJ, Christopoulos A, Capuano B, and Lane JR (2014) Biased agonism at G protein-coupled receptors: the promise and the challenges - a medicinal chemistry perspective. Med Res Rev 34:1286-1330.
23. Siehler S (2009) Regulation of RhoGEF proteins by G12/13-coupled receptors. Br J Pharmacol 158:41-49.
24. Suzuki H, Kimura K, Shirai H, Eguchi K, Higuchi S, Hinoki A, Ishimaru K, Brailoiu E, Dhanasekaran DN, and Stemmle LN et al. (2009) Endothelial nitric oxide synthase inhibits G12/13 and rho-kinase activated by the angiotensin II type-1 receptor: implication in vascular migration. Arterioscler Thromb Vasc Biol 29:217-224.
25. Tian Y, Smith RD, Balla T, and Catt KJ (1998) Angiotensin II activates mitogen-activated protein kinase via protein kinase C and Ras/Raf-1 kinase in bovine adrenal glomerulosa cells. Endocrinology 139:1801-1809.
26. Ushio-Fukai M, Griendling KK, Akers M, Lyons PR, and Alexander RW (1998) Temporal dispersion of activation of phospholipase C-beta1 and -gamma isoforms by angiotensin II in vascular smooth muscle cells. Role of alphaq/11, alpha12, and beta gamma G protein subunits. J Biol Chem 273:19772-19777.
27. van der Westhuizen ET, Breton B, Christopoulos A, and Bouvier M (2014) Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy. Mol Pharmacol 85:492-509.
28. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, and Lark MW (2010) Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335:572-579.
29. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, and Lefkowitz RJ (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100:10782-10787.
30. Wu-Zhang AX and Newton AC (2013) Protein kinase C pharmacology: refining the toolbox. Biochem J 452:195-209.
31. Zhao Y, Liu J, Li L, Liu L, and Wu L (2005) Role of Ras/PKCzeta/MEK/ERK1/2 signaling pathway in angiotensin II-induced vascular smooth muscle cell proliferation. Regul Pept 128:43-50.
32. Zhou L, Lovell KM, Frankowski KJ, Slauson SR, Phillips AM, Streicher JM, Stahl E, Schmid CL, Hodder P, and Madoux F et al. (2013) Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem 288:36703-36716.
33. Zimmerman B, Beautrait A, Aguila B, Charles R, Escher E, Claing A, Bouvier M, and Laporte SA (2012) Differential β-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs. Sci Signal 5:ra33.